MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers

PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patien...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Fricke, Stephanie L., Payne, Susan N., Favreau, Peter F., Kratz, Jeremy D., Pasch, Cheri A., Foley, Tyler M., Yueh, Alexander E., Van De Hey, Dana R., Depke, Mitchell G., Korkos, Demetra P., Sha, Gioia Chengcheng, DeStefanis, Rebecca A., Clipson, Linda, Burkard, Mark E., Lemmon, Kayla K., Parsons, Benjamin M., Kenny, Paraic A., Matkowskyj, Kristina A., Newton, Michael A., Skala, Melissa C., Deming, Dustin A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363831/
https://ncbi.nlm.nih.gov/pubmed/30425131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0510
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia